HOOFDDORP, Netherlands: IGEA Pharma N.V. announced a further extension of the partnership with Acalis by signing an agreement for the wholesale distribution of the Alzheimer’s prevention kit ‘Alz1’ in the US.
IGEA and Acalis started to partner on a commercial basis beginning 2020 for exclusive distribution in Middle East and some European and South American countries, including Belgium, Chile, Colombia, Uruguay and Peru, of IGEA’s products and solutions. The partnership extends now to the US, where yearly 500’000 people over 65 develop Alzheimer (which is someone every 65 seconds), 5.6 million people over 65 has Alzheimer and 16 million people daily take care about them.
IGEA will continue to distribute Alz1 on its e-commerce platform, and together with this new license agreement, IGEA expects to strengthen the market position of Alz1 with a substantial impact on its net revenues.
Under the terms of the agreement, the commercialization of Alz1 on a wholesale basis is expected to start within the next six months. In addition to supplying Alz1, IGEA will also provide certain services to Acalis including lab testing and data management and get an expected double-digit license fee determined pursuant to a shared risk-reward concept.
Acalis is an international healthcare group whose goal is to maximize the standards of comfort in care around the world. Acalis and AcalisCare are brands that today represent a seal of quality in the field of global elderly care, home care, rehabilitation, and post-hospital support with more than 40 centers, over 3,000 beds and more than 2,600 employees. As such, Acalis is one of the most global private home care and assistance providers in Europe, Latin America and Middle East, in particular Saudi Arabia and Turkey, and is expanding in Asia and North America.